 Manali Kamdar
Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 17 | 2023 | 97 | 6.280 |
Why?
| | Lymphoma, Mantle-Cell | 8 | 2023 | 18 | 3.100 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 9 | 2023 | 56 | 2.770 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 24 | 2023 | 1356 | 2.440 |
Why?
| | Hematopoietic Stem Cell Transplantation | 9 | 2023 | 519 | 2.290 |
Why?
| | Lymphoma, B-Cell | 5 | 2022 | 87 | 2.260 |
Why?
| | Neoplasm Recurrence, Local | 15 | 2023 | 850 | 1.430 |
Why?
| | Rituximab | 11 | 2023 | 148 | 1.350 |
Why?
| | Lymphoma | 2 | 2022 | 176 | 1.280 |
Why?
| | Immunotherapy, Adoptive | 10 | 2024 | 184 | 1.270 |
Why?
| | Immunoconjugates | 5 | 2023 | 87 | 1.260 |
Why?
| | Neoplasms, Second Primary | 2 | 2020 | 92 | 1.230 |
Why?
| | Antibodies, Bispecific | 2 | 2024 | 32 | 1.090 |
Why?
| | Bendamustine Hydrochloride | 5 | 2022 | 11 | 1.010 |
Why?
| | Antibodies, Monoclonal | 6 | 2023 | 1257 | 0.990 |
Why?
| | Neutropenia | 2 | 2023 | 123 | 0.930 |
Why?
| | Thrombocytopenia | 2 | 2023 | 177 | 0.890 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2021 | 660 | 0.820 |
Why?
| | Mediastinal Neoplasms | 3 | 2017 | 32 | 0.810 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 2 | 2022 | 11 | 0.760 |
Why?
| | Burkitt Lymphoma | 4 | 2021 | 52 | 0.710 |
Why?
| | Antineoplastic Agents | 6 | 2023 | 1875 | 0.690 |
Why?
| | Positron-Emission Tomography | 2 | 2018 | 260 | 0.680 |
Why?
| | Hodgkin Disease | 4 | 2023 | 121 | 0.650 |
Why?
| | Lymphoma, Follicular | 1 | 2019 | 34 | 0.650 |
Why?
| | Antigens, CD19 | 4 | 2023 | 91 | 0.650 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 67 | 0.640 |
Why?
| | Bone Marrow | 3 | 2021 | 243 | 0.630 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2017 | 193 | 0.620 |
Why?
| | Lymphoproliferative Disorders | 1 | 2018 | 46 | 0.590 |
Why?
| | Prognosis | 12 | 2023 | 3315 | 0.590 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2018 | 115 | 0.580 |
Why?
| | Humans | 59 | 2024 | 114043 | 0.570 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 16 | 0.560 |
Why?
| | Cancer Survivors | 1 | 2019 | 205 | 0.510 |
Why?
| | Transplantation, Autologous | 4 | 2023 | 175 | 0.490 |
Why?
| | Adult | 29 | 2023 | 30375 | 0.490 |
Why?
| | Cyclophosphamide | 5 | 2023 | 214 | 0.440 |
Why?
| | Doxorubicin | 5 | 2023 | 286 | 0.420 |
Why?
| | Vincristine | 4 | 2023 | 98 | 0.410 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2023 | 70 | 0.370 |
Why?
| | Retrospective Studies | 15 | 2023 | 12521 | 0.350 |
Why?
| | Central Nervous System Neoplasms | 2 | 2022 | 125 | 0.340 |
Why?
| | Brain Neoplasms | 1 | 2017 | 966 | 0.330 |
Why?
| | Middle Aged | 19 | 2023 | 26605 | 0.320 |
Why?
| | Dexamethasone | 2 | 2022 | 316 | 0.320 |
Why?
| | Aged | 17 | 2023 | 18969 | 0.310 |
Why?
| | Kaplan-Meier Estimate | 6 | 2021 | 813 | 0.310 |
Why?
| | Graft vs Host Disease | 3 | 2020 | 212 | 0.300 |
Why?
| | Cord Blood Stem Cell Transplantation | 2 | 2020 | 91 | 0.300 |
Why?
| | Transplantation Conditioning | 5 | 2021 | 149 | 0.300 |
Why?
| | Medical Oncology | 2 | 2020 | 229 | 0.280 |
Why?
| | Aged, 80 and over | 11 | 2022 | 6306 | 0.260 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 3 | 2023 | 172 | 0.260 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2023 | 56 | 0.260 |
Why?
| | Proportional Hazards Models | 4 | 2023 | 1078 | 0.250 |
Why?
| | Male | 20 | 2022 | 55396 | 0.250 |
Why?
| | Standard of Care | 2 | 2022 | 62 | 0.240 |
Why?
| | Etoposide | 3 | 2023 | 149 | 0.240 |
Why?
| | Female | 20 | 2022 | 59325 | 0.230 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 15 | 0.220 |
Why?
| | Treatment Outcome | 12 | 2023 | 9049 | 0.220 |
Why?
| | Tumor Lysis Syndrome | 1 | 2023 | 7 | 0.220 |
Why?
| | Neoplasm Staging | 4 | 2020 | 1162 | 0.220 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2022 | 80 | 0.190 |
Why?
| | Sulfonamides | 2 | 2022 | 444 | 0.190 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 136 | 0.190 |
Why?
| | SEER Program | 2 | 2019 | 195 | 0.190 |
Why?
| | Immunotherapy | 2 | 2023 | 473 | 0.180 |
Why?
| | Piperidines | 1 | 2022 | 159 | 0.180 |
Why?
| | Cisplatin | 1 | 2022 | 262 | 0.180 |
Why?
| | Disease Management | 3 | 2021 | 556 | 0.180 |
Why?
| | Methotrexate | 1 | 2022 | 227 | 0.180 |
Why?
| | Chlorambucil | 1 | 2020 | 8 | 0.180 |
Why?
| | Risk Factors | 4 | 2023 | 8614 | 0.170 |
Why?
| | Pyrazines | 1 | 2020 | 71 | 0.170 |
Why?
| | Benzamides | 1 | 2020 | 168 | 0.160 |
Why?
| | Pyrimidines | 1 | 2022 | 374 | 0.160 |
Why?
| | Antiviral Agents | 2 | 2021 | 642 | 0.160 |
Why?
| | Pyrazoles | 1 | 2022 | 361 | 0.160 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2023 | 533 | 0.160 |
Why?
| | Young Adult | 8 | 2022 | 10444 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2019 | 241 | 0.160 |
Why?
| | Recurrence | 3 | 2018 | 925 | 0.150 |
Why?
| | Thiotepa | 1 | 2018 | 19 | 0.150 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 1117 | 0.150 |
Why?
| | Herpes Zoster | 1 | 2022 | 330 | 0.150 |
Why?
| | Leukemia, Hairy Cell | 1 | 2017 | 6 | 0.150 |
Why?
| | Leukemia, B-Cell | 1 | 2017 | 11 | 0.150 |
Why?
| | Radiopharmaceuticals | 1 | 2018 | 158 | 0.140 |
Why?
| | Follow-Up Studies | 4 | 2021 | 4392 | 0.140 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 256 | 0.140 |
Why?
| | HIV Infections | 2 | 2021 | 2453 | 0.140 |
Why?
| | Prednisolone | 1 | 2017 | 75 | 0.140 |
Why?
| | Symptom Assessment | 1 | 2018 | 119 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2020 | 615 | 0.140 |
Why?
| | ROC Curve | 1 | 2018 | 441 | 0.140 |
Why?
| | Adolescent | 6 | 2022 | 17800 | 0.140 |
Why?
| | Fatal Outcome | 1 | 2017 | 281 | 0.130 |
Why?
| | Survivors | 1 | 2019 | 412 | 0.130 |
Why?
| | United States | 9 | 2021 | 12137 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 334 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 326 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 224 | 0.120 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1735 | 0.120 |
Why?
| | Societies, Medical | 1 | 2019 | 655 | 0.120 |
Why?
| | Disease-Free Survival | 3 | 2021 | 618 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1204 | 0.120 |
Why?
| | Survival Analysis | 4 | 2020 | 1206 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2018 | 641 | 0.110 |
Why?
| | Incidence | 1 | 2020 | 2314 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2018 | 479 | 0.110 |
Why?
| | Cell Differentiation | 1 | 2019 | 1695 | 0.100 |
Why?
| | Prednisone | 2 | 2023 | 229 | 0.100 |
Why?
| | Prevalence | 1 | 2018 | 2247 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2018 | 828 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 211 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2023 | 116 | 0.090 |
Why?
| | Infant, Newborn | 1 | 2019 | 5038 | 0.080 |
Why?
| | Gene Rearrangement | 2 | 2021 | 135 | 0.080 |
Why?
| | Remission Induction | 2 | 2020 | 233 | 0.070 |
Why?
| | Infant | 3 | 2019 | 7943 | 0.070 |
Why?
| | Immunophenotyping | 2 | 2020 | 274 | 0.070 |
Why?
| | Child, Preschool | 3 | 2019 | 9114 | 0.070 |
Why?
| | Transplantation, Homologous | 2 | 2020 | 377 | 0.070 |
Why?
| | Survival Rate | 2 | 2021 | 1638 | 0.070 |
Why?
| | Clarithromycin | 2 | 1997 | 26 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2159 | 0.060 |
Why?
| | Lactate Dehydrogenases | 1 | 2023 | 5 | 0.060 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1032 | 0.050 |
Why?
| | North America | 1 | 2023 | 255 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2023 | 148 | 0.050 |
Why?
| | Retreatment | 1 | 2022 | 67 | 0.050 |
Why?
| | Bleomycin | 1 | 2023 | 228 | 0.050 |
Why?
| | Child | 3 | 2019 | 18400 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2022 | 101 | 0.050 |
Why?
| | Consensus | 1 | 2024 | 532 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2022 | 104 | 0.050 |
Why?
| | Cohort Studies | 2 | 2021 | 4883 | 0.050 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2021 | 107 | 0.050 |
Why?
| | United Kingdom | 1 | 2021 | 226 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2020 | 73 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2024 | 1036 | 0.040 |
Why?
| | Australia | 1 | 2021 | 205 | 0.040 |
Why?
| | Europe | 1 | 2021 | 332 | 0.040 |
Why?
| | Organizations, Nonprofit | 1 | 2020 | 17 | 0.040 |
Why?
| | Canada | 1 | 2021 | 320 | 0.040 |
Why?
| | Central Nervous System | 1 | 2021 | 230 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 949 | 0.040 |
Why?
| | Comorbidity | 1 | 2023 | 1447 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2018 | 61 | 0.040 |
Why?
| | Fetal Blood | 1 | 2020 | 268 | 0.040 |
Why?
| | Mutation | 2 | 2020 | 3338 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 21 | 0.040 |
Why?
| | Vidarabine | 1 | 2018 | 26 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 152 | 0.040 |
Why?
| | Lymphocytes | 1 | 2020 | 327 | 0.040 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 72 | 0.040 |
Why?
| | Chronic Disease | 1 | 2023 | 1577 | 0.040 |
Why?
| | Cytodiagnosis | 1 | 2017 | 29 | 0.040 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2017 | 72 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 247 | 0.040 |
Why?
| | Tonsillitis | 1 | 1997 | 6 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2020 | 415 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 1422 | 0.030 |
Why?
| | Streptococcus pyogenes | 1 | 1997 | 30 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 445 | 0.030 |
Why?
| | Pharyngitis | 1 | 1997 | 23 | 0.030 |
Why?
| | Penicillins | 1 | 1997 | 52 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2017 | 127 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2017 | 191 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2016 | 98 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 636 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1624 | 0.030 |
Why?
| | Streptococcal Infections | 1 | 1997 | 127 | 0.030 |
Why?
| | Propensity Score | 1 | 2016 | 225 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 784 | 0.030 |
Why?
| | Radiotherapy | 1 | 2015 | 175 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2016 | 199 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 926 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1331 | 0.030 |
Why?
| | Amoxicillin | 1 | 1993 | 20 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 1218 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1310 | 0.030 |
Why?
| | Gene Expression | 1 | 2017 | 1417 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2343 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6195 | 0.020 |
Why?
| | Otitis Media | 1 | 1993 | 142 | 0.020 |
Why?
| | Registries | 1 | 2016 | 1764 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1997 | 1471 | 0.020 |
Why?
| | Time Factors | 1 | 2015 | 6077 | 0.020 |
Why?
| | Suspensions | 1 | 1993 | 30 | 0.010 |
Why?
| | Family Practice | 1 | 1997 | 426 | 0.010 |
Why?
| | Intestinal Absorption | 1 | 1993 | 93 | 0.010 |
Why?
| | Single-Blind Method | 1 | 1993 | 259 | 0.010 |
Why?
| | Administration, Oral | 1 | 1993 | 725 | 0.010 |
Why?
| | Acute Disease | 1 | 1993 | 907 | 0.010 |
Why?
| | Body Weight | 1 | 1993 | 868 | 0.000 |
Why?
|
|
Kamdar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|